Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

Highlights from the third day included information about Quanterix's new SIMOA One platform, expected to launch at the end of ...

After several years in the doldrums, pharmaceutical companies and biotechs expect an uptick in dealmaking in 2025, with some ...

Medicare Advantage (MA) insurers Alignment Healthcare and Clover Health both reported increased membership growth ahead of ...

The current head of the Center for Medicare has advice for her successor: "Engaging everyone in the ecosystem" is the ...

Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...